Sign in
4

Changes in Ownership

Viking Therapeutics, Inc. Filed Acc 0001209191-23-024227

Chief Financial Officer sold 97,839 shares at an average $18.00 ($1,761,310)

  • Chief Financial Officer acquired 97,839 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

ZANTE GREG · Chief Financial Officer

Table I: Non-derivative

8 lines
Date Transaction Shares Price Value Owned after D/I
2023-04-11 Exercise or conversion : show line 1 in the form +3,242 $7.77 $25,190 152,521 D
2023-04-11 Exercise or conversion : show line 2 in the form +8,500 $4.68 $39,780 161,021 D
2023-04-11 Exercise or conversion : show line 3 in the form +30,000 $4.88 $146,400 191,021 D
2023-04-11 Exercise or conversion : show line 4 in the form +14,553 $5.80 $84,407 205,574 D
2023-04-11 Sale : show line 5 in the form −56,295 $18.00 $1,013,518 149,279 D
2023-04-12 Exercise or conversion : show line 6 in the form +37,447 $5.80 $217,193 186,726 D
2023-04-12 Exercise or conversion : show line 7 in the form +4,097 $7.77 $31,834 190,823 D
2023-04-12 Sale : show line 8 in the form −41,544 $18.00 $747,792 149,279 D
Open-market sales · 97,839 sh · avg $18.00 · $1,761,310

Table II: Derivative

6 lines
Date Transaction Shares Owned after D/I
2023-04-11 Exercise or conversion : show line 9 in the form Stock Option (right to buy) −3,242 16,847 D
2023-04-11 Exercise or conversion : show line 10 in the form Stock Option (right to buy −8,500 8,500 D
2023-04-11 Exercise or conversion : show line 11 in the form Stock Option (right to buy −30,000 90,000 D
2023-04-11 Exercise or conversion : show line 12 in the form Stock Option (right to buy −14,553 63,447 D
2023-04-12 Exercise or conversion : show line 13 in the form Stock Option (right to buy −37,447 26,000 D
2023-04-12 Exercise or conversion : show line 14 in the form Stock Option (right to buy) −4,097 12,750 D
Loading xslF345X04/doc4.xml…